Gamma delta T cells are needed for ocular immune privilege and corneal graft survival.
It has been recognized for over a century that the anterior chamber of the eye is endowed with a remarkable immune privilege. One contributing component is the Ag-specific down-regulation of systemic delayed-type hypersensitivity (DTH) that is induced when Ags are introduced into the anterior chamber. This phenomenon, termed anterior chamber-associated immune deviation (ACAID), culminates in the generation of regulatory cells that inhibit the induction (afferent suppression) and expression (efferent suppression) of DTH. Since gamma delta T cells play a major role in other forms of immune regulation, we suspected they might contribute to the induction and expression of ACAID. Mice treated with anti-gamma delta Ab failed to develop ACAID following anterior chamber injection of either soluble Ag (OVA) or alloantigens (spleen cells). Additional experiments with knockout mice confirmed that mice lacking functional gamma delta T cells also fail to develop ACAID. Using a local adoptive transfer of DTH assay, we found that gamma delta T cells were required for the generation of regulatory T cells, but did not function as the efferent regulatory cells of ACAID. The importance of gamma delta T cells in corneal allograft survival was confirmed by blocking gamma delta T cells with GL3 Ab before corneal transplantation. While in vivo treatment with normal hamster serum had no effect on corneal graft survival, infusion of anti-gamma delta Ab resulted in a profound increase in corneal allograft rejection. Thus, gamma delta T cells are needed for sustaining at least one aspect of ocular immune privilege and for promoting corneal allograft survival.
Skelsey
M E
ME
Graduate Program in Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Mellon
J
J
Niederkorn
J Y
JY
D000818:Animals; D000867:Anterior Chamber / Q000276:immunology*; D000941:Antigens / Q000008:administration & dosage; D002454:Cell Differentiation / Q000276:immunology; D016039:Corneal Transplantation / Q000276:immunology*; D006085:Graft Survival / Q000235:genetics / Q000276:immunology*; D006968:Hypersensitivity, Delayed / Q000235:genetics / Q000276:immunology; D007165:Immunosuppression Therapy; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D007519:Isoantigens / Q000008:administration & dosage; D017710:Lymphocyte Transfusion; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008814:Mice, Inbred NZB; D018345:Mice, Knockout; D010047:Ovalbumin / Q000008:administration & dosage; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000172:deficiency / Q000235:genetics / Q000276:immunology*; D012995:Solubility; D013154:Spleen / Q000276:immunology / Q000637:transplantation; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology
D000941:Antigens; D007519:Isoantigens; D016692:Receptors, Antigen, T-Cell, gamma-delta; D010047:Ovalbumin